Pharma BD Deal Intelligence
Velcade franchise anchored Takeda U.S. oncology transformation with $20B+ lifecycle revenue
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Takeda acquired Millennium Pharmaceuticals for $8.8B for cancer drug research, including Velcade.
Takeda buys Millennium to build its U.S. business, with the acquisition accelerating Takeda's vision of becoming a global leader in oncology with critical mass…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Takeda Pharmaceutical Co. acquired Millennium Pharmaceuticals for $25 per share (~$8.8 billion) in an all-cash tender offer, gaining Velcade (bortezomib) for multiple myeloma ($528M in 2007 revenue) and establishing a major US oncology presence. This was the largest overseas acquisition by a Japanese pharmaceutical company at the time.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals (this deal) | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |
← Browse all deals · How we score deals
More: 2003 deals · Takeda Pharmaceutical Company Ltd. deals · Gastroenterology deals